Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment

Kyoung Soo Kim, Hyun Mi Choi, Hye In Ji, Ran Song, Hyung In Yang, Soo Kon Lee, Myung Chul Yoo, YongBeom Park

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The aim of this study was to determine whether disease activity and the type of therapy differentially modulate serum adipokine levels in patients with rheumatoid arthritis (RA), and whether pre-therapy adipokine levels contribute to resistance to treatment. Fasting blood samples from 40 RA patients were obtained at baseline and six months following therapeutic treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of adiponectin, leptin, visfatin and resistin were measured by ELISA. Baseline adipokine levels did not exhibit a statistically significant difference when comparing patients with moderate and high disease activity, based on the disease activity score in 28 joints (DAS28). Of all the adipokines, only adiponectin was significantly increased in patients responding to DMARDs and/or TNF-α blocker therapy, based on the American College of Rheumatology 20% improvement criteria (ACR20) at six months (2,964±1,237 to 3,683±1,511 ng/ml, P<0.01). However, adiponectin levels in non-responders did not significantly increase (3,192±2,090 to 3,222±1,150 ng/ml). By contrast, there were no statistically significant changes in leptin, resistin or visfatin levels in either the responders or non-responders. Serum adipokine (adiponectin, leptin, visfatin, and resistin) levels in RA patients did not significantly change following therapy, with the exception of adiponectin. Adipokine levels may not contribute to therapeutic resistance to DMARDs and/or TNF-α blocking agents.

Original languageEnglish
Pages (from-to)255-260
Number of pages6
JournalMolecular Medicine Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Adipokines
Adiponectin
Rheumatoid Arthritis
Nicotinamide Phosphoribosyltransferase
Resistin
Antirheumatic Agents
Leptin
Serum
Tumor Necrosis Factor-alpha
Therapeutics
Blood
Fasting
Joints
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Oncology
  • Cancer Research

Cite this

Kim, Kyoung Soo ; Choi, Hyun Mi ; Ji, Hye In ; Song, Ran ; Yang, Hyung In ; Lee, Soo Kon ; Yoo, Myung Chul ; Park, YongBeom. / Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment. In: Molecular Medicine Reports. 2014 ; Vol. 9, No. 1. pp. 255-260.
@article{166157f6779d48c3b5c4fe191864a4f5,
title = "Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment",
abstract = "The aim of this study was to determine whether disease activity and the type of therapy differentially modulate serum adipokine levels in patients with rheumatoid arthritis (RA), and whether pre-therapy adipokine levels contribute to resistance to treatment. Fasting blood samples from 40 RA patients were obtained at baseline and six months following therapeutic treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of adiponectin, leptin, visfatin and resistin were measured by ELISA. Baseline adipokine levels did not exhibit a statistically significant difference when comparing patients with moderate and high disease activity, based on the disease activity score in 28 joints (DAS28). Of all the adipokines, only adiponectin was significantly increased in patients responding to DMARDs and/or TNF-α blocker therapy, based on the American College of Rheumatology 20{\%} improvement criteria (ACR20) at six months (2,964±1,237 to 3,683±1,511 ng/ml, P<0.01). However, adiponectin levels in non-responders did not significantly increase (3,192±2,090 to 3,222±1,150 ng/ml). By contrast, there were no statistically significant changes in leptin, resistin or visfatin levels in either the responders or non-responders. Serum adipokine (adiponectin, leptin, visfatin, and resistin) levels in RA patients did not significantly change following therapy, with the exception of adiponectin. Adipokine levels may not contribute to therapeutic resistance to DMARDs and/or TNF-α blocking agents.",
author = "Kim, {Kyoung Soo} and Choi, {Hyun Mi} and Ji, {Hye In} and Ran Song and Yang, {Hyung In} and Lee, {Soo Kon} and Yoo, {Myung Chul} and YongBeom Park",
year = "2014",
month = "1",
day = "1",
doi = "10.3892/mmr.2013.1764",
language = "English",
volume = "9",
pages = "255--260",
journal = "Molecular Medicine Reports",
issn = "1791-2997",
publisher = "Spandidos Publications",
number = "1",

}

Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment. / Kim, Kyoung Soo; Choi, Hyun Mi; Ji, Hye In; Song, Ran; Yang, Hyung In; Lee, Soo Kon; Yoo, Myung Chul; Park, YongBeom.

In: Molecular Medicine Reports, Vol. 9, No. 1, 01.01.2014, p. 255-260.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment

AU - Kim, Kyoung Soo

AU - Choi, Hyun Mi

AU - Ji, Hye In

AU - Song, Ran

AU - Yang, Hyung In

AU - Lee, Soo Kon

AU - Yoo, Myung Chul

AU - Park, YongBeom

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The aim of this study was to determine whether disease activity and the type of therapy differentially modulate serum adipokine levels in patients with rheumatoid arthritis (RA), and whether pre-therapy adipokine levels contribute to resistance to treatment. Fasting blood samples from 40 RA patients were obtained at baseline and six months following therapeutic treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of adiponectin, leptin, visfatin and resistin were measured by ELISA. Baseline adipokine levels did not exhibit a statistically significant difference when comparing patients with moderate and high disease activity, based on the disease activity score in 28 joints (DAS28). Of all the adipokines, only adiponectin was significantly increased in patients responding to DMARDs and/or TNF-α blocker therapy, based on the American College of Rheumatology 20% improvement criteria (ACR20) at six months (2,964±1,237 to 3,683±1,511 ng/ml, P<0.01). However, adiponectin levels in non-responders did not significantly increase (3,192±2,090 to 3,222±1,150 ng/ml). By contrast, there were no statistically significant changes in leptin, resistin or visfatin levels in either the responders or non-responders. Serum adipokine (adiponectin, leptin, visfatin, and resistin) levels in RA patients did not significantly change following therapy, with the exception of adiponectin. Adipokine levels may not contribute to therapeutic resistance to DMARDs and/or TNF-α blocking agents.

AB - The aim of this study was to determine whether disease activity and the type of therapy differentially modulate serum adipokine levels in patients with rheumatoid arthritis (RA), and whether pre-therapy adipokine levels contribute to resistance to treatment. Fasting blood samples from 40 RA patients were obtained at baseline and six months following therapeutic treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of adiponectin, leptin, visfatin and resistin were measured by ELISA. Baseline adipokine levels did not exhibit a statistically significant difference when comparing patients with moderate and high disease activity, based on the disease activity score in 28 joints (DAS28). Of all the adipokines, only adiponectin was significantly increased in patients responding to DMARDs and/or TNF-α blocker therapy, based on the American College of Rheumatology 20% improvement criteria (ACR20) at six months (2,964±1,237 to 3,683±1,511 ng/ml, P<0.01). However, adiponectin levels in non-responders did not significantly increase (3,192±2,090 to 3,222±1,150 ng/ml). By contrast, there were no statistically significant changes in leptin, resistin or visfatin levels in either the responders or non-responders. Serum adipokine (adiponectin, leptin, visfatin, and resistin) levels in RA patients did not significantly change following therapy, with the exception of adiponectin. Adipokine levels may not contribute to therapeutic resistance to DMARDs and/or TNF-α blocking agents.

UR - http://www.scopus.com/inward/record.url?scp=84893828861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893828861&partnerID=8YFLogxK

U2 - 10.3892/mmr.2013.1764

DO - 10.3892/mmr.2013.1764

M3 - Article

VL - 9

SP - 255

EP - 260

JO - Molecular Medicine Reports

JF - Molecular Medicine Reports

SN - 1791-2997

IS - 1

ER -